Navigation Links
Common alternative treatment for liver disease is found to be ineffective

Results of high-quality randomized clinical trials have determined that milk thistle extract, a widely used alternative medication, may not have any significant influence on the course of patients with alcoholic liver disease or hepatitis B or C liver disease. These findings are published in The American Journal of Gastroenterology.

According to the previous studies, milk thistle extracts have been shown to possess properties that protect against various hepatotoxins, including the prevention of lipid perioxidation, which is frequent in all stages of liver damage in alcoholic and non-alcoholic liver disease.

"The ironic fact is," notes Christian Gluud of the Copenhagen Trial Unit, Center for Clinical Intervention Research at the Copenhagen University Hospital, "that even though milk thistle and milk thistle extracts have been widely examined, we are still not in a situation where we can exclude a potential beneficial or harmful effect."

In this study, researchers aimed to determine the exact benefits or harm in using milk thistle to treat affected patients. Over 900 patients with the aforementioned types of liver disease were studied in these trials over a period of six months, in groups treated with milk thistle versus placebo treatment. No significant effects were observed on mortality or complication of the disease. Further, milk thistle was not associated with any significant risk of adverse events.

"It would be logical to stop the use of milk thistle products, not to reimburse any use, to stop the information that milk thistle products may be used, and to support further trials," adds Gluud.


'"/>

Source:Blackwell Publishing Ltd.


Page: 1

Related biology news :

1. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
2. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
3. Men Estimate Mens Risks Of Common Disorders Higher Than Women Do, And Vice Versa
4. Use of Antibiotics for Acne May Increase Risk of Common Illness
5. Common viruses may cause cancer
6. Common molecular signature identified in solid tumors
7. Common bacteria pirate natural mechanism to get inside cells
8. Commonly used antidepressants may also affect human immune system
9. Common practices at petting zoos put visitors at risk
10. Common enzyme is a key player in DNA repair
11. Common molecular signature identified in solid tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology: